[{"id":"95abdf38-6738-44e7-ab64-5954c4b903b6","acronym":"","url":"https://clinicaltrials.gov/study/NCT00598169","created_at":"2022-07-18T07:54:14.583Z","updated_at":"2024-07-02T16:36:42.203Z","phase":"Phase 1","brief_title":"Bortezomib, Ifosfamide, Carboplatin, and Etoposide, With or Without Rituximab, in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin Lymphoma","source_id_and_acronym":"NCT00598169","lead_sponsor":"AIDS Malignancy Consortium","biomarkers":" APOBEC3G","pipe":"","alterations":" ","tags":["APOBEC3G"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • Rituxan (rituximab) • bortezomib • ifosfamide • etoposide IV • dexamethasone • dexamethasone injection"],"overall_status":"Completed","enrollment":" Enrollment 23","initiation":"Initiation: 11/01/2007","start_date":" 11/01/2007","primary_txt":" Primary completion: 10/01/2014","primary_completion_date":" 10/01/2014","study_txt":" Completion: 11/01/2014","study_completion_date":" 11/01/2014","last_update_posted":"2020-08-10"}]